Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects

OBJECTIVES: The aim of this study was to assess the pharmacokinetics (PK) and safety/tolerability of siponimod in healthy subjects when coadministered with (1) the moderate cytochrome P450 (CYP) 2C9 and CYP3A inhibitor fluconazole (Study A), and (2) with three different CYP2C9 genotype variants (Stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardin, Anne, Ufer, Mike, Legangneux, Eric, Rossato, Gianluca, Jin, Yi, Su, Zhenzhong, Pal, Parasar, Li, Wenkui, Shakeri-Nejad, Kasra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373376/
https://www.ncbi.nlm.nih.gov/pubmed/30088221
http://dx.doi.org/10.1007/s40262-018-0700-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373376/
https://www.ncbi.nlm.nih.gov/pubmed/30088221
http://dx.doi.org/10.1007/s40262-018-0700-3

Ejemplares similares